References
Slany RK (2005) When epigenetics kills: MLL fusion proteins in leukemia. Hematol Oncol 23:1–9
Sobulo OM, Borrow J, Tomek R et al (1997) MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc Natl Acad Sci USA 94:8732–8737
Prince HM, Bishton MJ, Harrison SJ (2009) Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 15:3958–3969
Prince HM, Bishton MJ, Johnstone RW (2009) Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol 5:601–612
Neff T, Armstrong SA (2009) Chromatin maps, histone modifications and leukemia. Leukemia 23:1243–1251
Slany RK (2009) The molecular biology of mixed lineage leukemia. Haematologica 94:984–993
Dou Y, Hess JL (2008) Mechanisms of transcriptional regulation by MLL and its disruption in acute leukemia. Int J Hematol 87:10–18
Eklund EA (2007) The role of HOX genes in malignant myeloid disease. Curr Opin Hematol 14:85–89
Khobta A, Carlo-Stella C, Capranico G (2004) Specific histone patterns and acetylase/deacetylase activity at the breakpoint-cluster region of the human MLL gene. Cancer Res 64:2656–2662
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Burbury, K.L., Bishton, M.J., Johnstone, R.W. et al. MLL-aberrant leukemia: complete cytogenetic remission following treatment with a histone deacetylase inhibitor (HDACi). Ann Hematol 90, 847–849 (2011). https://doi.org/10.1007/s00277-010-1099-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-010-1099-6